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Abstract
Obesity is associated with metabolic derangements such as insulin resistance, inflammation and hypercoagulobility
which can all be understood as consequences of adipose tissue dysfunction. The potential role for adipose tissue
derived cytokines and adipokines in the development of vascular disease and diabetes may produce a clinical
need to influence adipose tissue function. Various pharmacological and non-pharmacological interventions affect
plasma cytokine and adipokine levels. The effects of these interventions depend on weight loss per se, changes in
fat distribution without weight loss and/or direct effects on adipose tissue inflammation.
Weight loss, as a result of diet, pharmacology and surgery, positively influences plasma adipokines and systemic
inflammation. Several classes of drugs influence systemic inflammation directly through their anti-inflammatory
actions. PPAR-g agonism positively influences adipose tissue inflammation in several classes of intervention such as
the thiazolidinediones and perhaps salicylates, CB1-antagonists and angiotensin II receptor blockers. Furthermore,
within drug classes there are differential effects of individual pharmacologic agents on adipose tissue function.
It can be concluded that several commonly used pharmacological and non-pharmacological interventions have
unintended influences on adipose tissue function. Improving adipose tissue function may contribute to reducing
the risk of vascular diseases and the development of type 2 diabetes.
Introduction
The prevalence of obesity is rising worldwide [1]. As
obesity is a major cause of insulin resistance, metabolic
syndrome, type 2 diabetes, atherosclerosis and prema-
ture death, the incidence of these diseases is expected to
rise. Imbalance between caloric intake and energy
expenditure leads to hypertrophy and hyperplasia of adi-
pose tissue [2], leading to metabolic derangements, such
as dyslipidemia, elevated blood pressure, inflammation,
hypercoagulobility, as a consequence of adipose tissue
dysfunction [3-5].
Adipose tissue dysfunction can be viewed as a combi-
nation of pro-inflammatory changes in adipose tissue
and changes in the endocrine function of adipose tissue
as witnessed by changes in plasma cytokine and espe-
cially plasma adipokine levels. Visceral adipose tissue
(VAT) is the predominant adipose tissue compartment
responsible for the production of proinflammatory cyto-
kines and adipokines [6].
Various mechanisms are implicated in the initial
phases of adipose tissue inflammation, most of which
are a result of adipose tissue expansion [7]. The histo-
pathology of adipose tissue inflammation in obesity is
characterized by accumulation of macrophages in adi-
pose tissue [8]. Subsequent adipose tissue inflammation
leads to the systemic release of cytokines and adipokines
by inflammatory cells, preadipocytes and adipocytes.
Although most of the cytokines and adipokines are not
solely produced by adipose tissue, they do reflect the
vast production capacity of adipose tissue as exampled
by the 30% contribution of adipose tissue on systemic
IL-6 plasma levels [9]. As adipose tissue contributes sig-
nificantly to systemic concentrations of cytokines and
adipokines, plasma concentrations can therefore be
regarded as a reflection of adipose tissue dysfunction.
The potential role for adipose tissue derived cytokines
and adipokines in the development of vascular disease
and diabetes [10-13] may produce a clinical need to
influence adipose tissue function. Various pharmacologi-
cal and non-pharmacological interventions, already com-
monly used in patients with vascular disease or type 2
diabetes affect adipose tissue function. The effects of
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ticularly on a loss of fat mass, changes in fat distribution
without weight loss and/or direct effects on adipose tis-
sue inflammation. In this paper we review the current
pharmacological and non-pharmacological options and
their possible underlying mechanisms for influencing
adipose tissue function.
Effects of weight loss on adipose tissue function
The quantity of adipose tissue is an important driver of
adipose tissue dysfunction, insulin resistance and cardio-
vascular disease. Therefore, to improve adipose tissue
function the logical and preferred first step should be to
decrease the amount of (visceral) adipose tissue. Decreas-
ing the amount of visceral adipose tissue may be accom-
plished via the following mechanisms: weight loss per se,
loss of fat mass with an increase in fat-free mass (such as
seen with exercise) or by inducing a shift in fat distribu-
tion from visceral to subcutaneous compartments.
Although not a subject of this review, altering dietary
content without altering the caloric content, such as by
reducing fructose intake may also have beneficial effects
on adipose tissue function [10]. For example, in an isoca-
loric diet, fructose rather than glucose intake was asso-
ciated with an increase in visceral adipose tissue in
humans [14] while fructose intake in mice induces visc-
eral and perivascular adipose tissue dysfunction [15,16].
Diet-induced weight loss
Intentional weight loss is associated with lowering blood
pressure in hypertensive patients, improvements in the
lipid profile and a decreased incidence of diabetes
[17-19]. Intentional weight loss induced by taking dietary
measures improves endothelial function [20-22], lowers
systemic markers of inflammation [23] and ameliorates
insulin resistance [24]. In patients with and without the
metabolic syndrome, 7% weight loss already reduced the
prevalence of components of the metabolic syndrome
such as systolic blood pressure, plasma glucose levels, tri-
glycerides and high-density lipoprotein (HDL) cholesterol
[25]. Although there are no randomized controlled trials
(RCT) available showing the benefit of diet induced
weight reduction on overall or cardiovascular mortality
there is a clear association between obesity and mortality
[26-28]. The currently ongoing Look AHEAD trial com-
pares intensive lifestyle intervention including weight loss
with diabetes support and education and has shown pro-
mising results on diabetes control and cardiovascular risk
factors [18]. Influencing plasma adipokines levels such as
adiponectin by a dietary intervention seems especially
dependent on a reduction in fat mass [29].
Lowering the daily caloric intake by 500 kilocalories
leads to a decrease in bodyweight between 5-10% and a
decrease in body mass index (BMI) by 2.0 and 2.9 kg/
m2 [30-32]. This weight loss was associated with a 25%
fall in leptin plasma concentrations while there was no
effect on adiponectin levels [30,32]. Weight loss of 5-
10% increases insulin sensitivity while marginally
increasing plasma levels of adiponectin and reducing
plasma levels of C-reactive protein (CRP), interleukin-6
(IL-6) and the soluble tumour necrosis factor-a (TNF-
a) receptor without an effect on plasma levels of TNF-
a, indicating an improvement in adipose tissue function
[31,32].
If caloric intake is further restricted by 600-1000 kcal/
day, bodyweight decreases between 7 and 12% [25,33]
resulting in a 46-58% fall in plasma leptin levels and an
increase of 42-65% in adiponectin levels [25]. Appar-
ently, diet-induced weight loss is an effective strategy for
improving adipose tissue function but at least 10%
weight loss is needed to improve plasma concentrations
of adiponectin and inflammatory markers such as CRP.
[34] Besides the amount of weight loss the duration of
the weight loss period might also influence plasma adi-
ponectin levels with adiponectin levels increasing during
the weight loss maintenance period after a weight loss
of 11-12% in 8 weeks [35].
Medication-induced weight loss
Orlistat
Orlistat is a lipase inhibitor that decreases intestinal fat
absorption after meals. Therefore, successful treatment
with orlistat should be seen as a combined treatment of
orlistat and a (low fat) diet. In a recent meta-analysis of
16 studies including 10,631 patients with a follow up of
1-4 years, orlistat reduced weight by 2.9 kg (95% CI 2.5-
3.2 kg) and increased absolute percentages of partici-
pants achieving 5% and 10% weight loss thresholds by
21% and 12% respectively [36]. A decrease in the inci-
dence of type 2 diabetes mellitus from 9.0% to 6.2%
(Hazard Ratio 0.63; 95% CI 0.46-0.86) was reported. [37]
Together with a dietary intervention, orlistat (120 mg
tid.) was not associated with a change in plasma leptin
and adiponectin concentrations, although resistin levels
decreased by 36% after 6 months of treatment. [38]
When orlistat was combined with a hypocaloric diet
with a 600 kcal restriction, bodyweight decreased by 14-
24%, percentage body fat by 21% and plasma concentra-
tions of leptin, CRP, IL-6, TNF-a, and resistin decreased
while adiponectin increased, indicating an improvement
in adipose tissue function [39,40].
Sibutramine
Sibutramine is a highly selective inhibitor for the reup-
take of norepinefrine and serotonin at nerve endings.
Originally developed as an anti-depressant, sibutramine
has effects on energy intake and to a lesser extent on
energy expenditure. The latter is probably mediated by
brown adipose tissue thermogenesis [41]. In a meta-
Westerink and Visseren Cardiovascular Diabetology 2011, 10:13
http://www.cardiab.com/content/10/1/13
Page 2 of 12analysis of placebo-controlled randomized trials, sibutra-
mine decreased bodyweight by 4.2 kg (95% CI
3.6-4.7 kg) [36]. Compared with placebo, sibutramine
however increased systolic blood pressure by 1.7 mmHg
(95% CI 0.1-3.3) and pulse rate by 4.5 beats/min (95%
CI 3.5-5.6). Other common side effects included dry
mouth, insomnia and nausea in 7-20%.
Two small studies evaluated the combined effect of a
500-600 kcal diet restriction and sibutramine (10-15 mg
daily). Bodyweight fell by only 5-7%, but plasma concen-
trations of TNF-a, IL-6, resistin, leptin and CRP levels
decreased [38,42]. In contrast to diet only, the combina-
tion of a diet with sibutramine was associated with an
increase in adiponectin and interleukin-10 (IL-10) levels
w h i l eo n l yi n d u c i n gar e l a t i v e l ys m a l lw e i g h tl o s s[ 4 2 ] .
Also, a 7% fall in bodyweight and 14% fall in fat mass
due to sibutramine was associated with improved insulin
resistance and a rise in adiponectin which was especially
correlated with the decrease in visceral adipose tissue
area [43]. The effect of sibutramine induced weight loss
on adipokines seems greater than in studies in which
caloric restriction is used. The question therefore arises
whether sibutramine may have effects on adipose tissue
function independent of sole weight loss. Catecholamine
induced lipolysis has been shown to be greater in visc-
eral adipose tissue (VAT) then in subcutaneous adipose
tissue (SAT) [44]. Indeed, combining a diet with sibutra-
mine led to a preferential loss of VAT in patients with
obstructive sleep apnea [45]. This potential preferential
effect on VAT may be an explanation for the greater
effect of sibutramine on adipokines and cytokines than
could be expected by similar weight loss with a diet
alone. However, recently it has been shown that use of
sibutramine is associated with an increased risk for non-
fatal myocardial infarction and stroke in patients at high
cardiovascular risk [46]. Since October 2010 sibutramine
has therefore been withdrawn from the market.
Cannabinoid-1 (CB1) receptor antagonists
The cannabinoid-1 (CB1) receptor is widely dispersed
throughout the body with high concentration in areas of
the brain related to feeding [47]. CB1 receptors are also
present on adipocytes [48]. The two best characterized
endocannabinoids, anandamide (AEA) and 2-arachnido-
nylglycerol (2-AG) are both capable of activating the
peroxisome proliferator-activated receptor (PPAR) a
and g [49]. This activation may be induced by direct
binding to PPAR or by intracellular signalling after CB
receptor activation (mediated by extracellular signal-
regulated kinase 1/2 (ERK1/2) and p38 mitogen-acivated
protein kinase (MAPK)) or by COX-2 metabolites of
endocannabinoids [49,50].
Interestingly enough, peripheral endocannabinoid
levels are increased in human obesity, probably due to
diminished insulin mediated down regulation of the
endocannabinoid system in insulin resistant adipocytes
[51,52]. The selective CB1 receptor blocker rimonabant
has been investigated as a weight reduction drug in sev-
eral large scale clinical trials [53-56]. Rimonabant not
only has central effects on satiety but also affects the
peripheral endocannabinoid system in the gut leading to
nausea and diarrhoea, all of which can explain the rimo-
nabant associated weight loss [57]. In a recent meta-ana-
lysis of placebo-controlled trials, evaluating the clinical
effects of rimonabant, it appeared that the mean weight
loss was 4.7 kg (95% CI 4.1-5.3) more than in the pla-
cebo group [36]. Furthermore, rimonabant significantly
reduced waist circumference, lowered blood pressure,
lowered triglyceride levels and increased high density
lipoprotein cholesterol plasma concentrations. Although
rimonabant was withdrawn from the market in 2008
due to adverse effects including an increased incidence
of psychiatric disorders (depression, suicidal ideation,
anxiety, and aggression), other CB1 receptor antagonists
are still under investigation.
In patients with type 2 diabetes, treatment with rimo-
nabant at the highest dose (20 mg) decreased CRP
(-26%) and leptin (-2%)levels [55]. In overweight or
obese patients with untreated dyslipidemia, rimonabant
decreased leptin levels to a greater extent than in
patients with diabetes (23%) and significantly increased
adiponectin levels by 37% [53]. In regression analysis
57% of the 1-year treatment effect of rimonabant on
adiponectin was thought not to be attributable to weight
loss [58]. Although not completely explained, these data
suggest that rimonabant may have effects on adiponec-
tin levels beyond weight loss. Adipocytes express a CB1
receptor and may therefore be a direct target for rimo-
nabant [48]. Also, unbound circulating endocannabi-
noids may still activate PPARs and may therefore
provide an explanation for weight loss independent
effects of rimonabant on adipose tissue function.
Bariatric surgery
Bariatric surgery is increasingly used as a strategy to
reduce bodyweight and thereby ameliorate risk factors
for cardiovascular disease [59-61]. On average, patients
lose 14-25% weight after bariatric surgery [62]. Patients
who underwent gastric bypass surgery showed a signifi-
cant decline in all-cause mortality as well as coronary
artery disease, diabetes and cancer during 7.1 years fol-
low up [26]. Patients with recently diagnosed type 2 dia-
betes showed greater weight loss after gastric banding
compared to conventional therapy (life style advice) as
well as a greater chance of remission of type 2 diabetes
[63]. This effect of bariatric surgery on diabetes is prob-
ably due to a reduction in body fat mass and, in the
case of gastric bypass surgery, changes in gut hormone
production such as Glucagon-Like Peptide-1 (GLP-1),
Gastric Inhibitory Polypeptide (GIP) and grehlin [64].
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while reducing expression of IL-6 and MCP-1 in 3T3-L1
adipocytes through the protein kinase A pathway [65].
Finally, although only limited data is present, plasma
GIP levels may important as seen from in vitro studies
showing a GIP induced reduction in insulin resistance
in 3T3-L1 adipocytes through activation of Akt [66].
Although only limited data isa v a i l a b l e ,t h ee f f e c t so f
GLP-1 and GIP on adipocytes may be part of the weight
loss independent effects of gastric bypass surgery on adi-
pose tissue function. Other beneficial effects of gastric
bypass surgery in comparison to gastric banding may
include a smaller fat mass to fat-free mass ratio with
similar weight loss [67].
Adiponectin levels have been shown to increase after
bariatric surgery in several small scale studies mainly
because of an increase in high molecular weight adipo-
nectin [68-70]. After bariatric surgery, plasma con-
centrations of Macrophage Inhibitory Factor (MIF),
Plasminogen Activator Inhibitor-1 (PAI-1), Retinol Bind-
ing Protein-4 (RBP-4), Monocyte Chemotactic Protein-1
(MCP-1) and interleukin-18 (IL-18) are decreased, indi-
cating positive effects on adipose tissue function [71-73].
Effects of exercise on adipose tissue function
The most important reason why insulin resistance
increases with age is the steady increase in bodyweight
and the reduction in physical activity [74]. Comparison
of studies investigating the effect of exercise and diet on
body weight is hampered by the different exercise sche-
dules, combination with different dietary restrictions
and different patient groups studied. Exercise does not
lead to preferential loss of VAT when comparing mod-
erate and vigorous exercise with dietary caloric restric-
tion, nor is there a clear difference in the change of
body composition [75] Both aerobic and strength exer-
cise lead to an amelioration of insulin resistance [24].
Even short duration exercise improves insulin resistance,
suggesting that some beneficial effects of exercise are
not mediated by weight loss [76].
In patients with type 2 diabetes mellitus, aerobic exer-
cise during 16 weeks was associated with a decrease in
bodyweight by only 1.3 kilograms and by lower plasma
concentrations of IL-6, IL-18, CRP and resistin showing
an anti-inflammatory effect of exercise with only mar-
ginal weight reduction [77]. Exercise may improve adi-
pose tissue function in healthy patients with the largest
effect in the older age group as shown by an increase in
plasma adiponectin levels and a decrease in plasma
RBP-4 levels [78]. A recent systemic review however
showed that most but not all studies investigating the
effect of exercise failed to show an effect on circulating
adiponectin levels probably due to the only limited
weight loss associated with pure exercise studies [78,79].
These findings are compatible with data from studies
investigating diet induced weight loss which showed
that more than 10% weight loss is needed to elevate
plasma adiponectin levels [34].
Effects of pharmacologic agents on adipose tissue
function
Salicylates
Salicylates are among the most commonly used nonsteroi-
dal anti-inflammatory drugs and have their main action
through cyclooxygenase (COX) inhibition. Studies investi-
gating the effects of salicylates on adipose tissue function
have especially implicated specific COX-2 inhibition as the
mechanism by which salicylates may improve adipose tis-
sue function [80,81]. Besides COX inhibition, salicylates
also act through inhibition of the activity of inhibitor of
nuclear factor kappa-B kinase subunit beta (IKK-b)l e a d i n g
to decreased phosphorylation of inhibitor of NF-B( I B)
and therefore to a reduction in translocation of Nuclear
Transcription factor kappa-B (NF-B) to the nucleus [82].
Besides the direct anti-inflammatory effects, some data
suggests a possible role of PPAR-g agonism which is of
great importance in adipocyte differentiation, function and
body fat composition. For example, 5-aminosalicylic acid
increases PPAR-gamma expression, promotes its translo-
cation from the cytoplasm to the nucleus, and permits the
recruitment of co-activators and the activation of a peroxi-
some-proliferator response element-driven gene in human
epithelial cells [83]
Although high dose acetylsalicylic acid (1 to 1,6 gram)
has been shown to reduce fasting and post load glucose
levels in patients with type 2 diabetes, the clinical use of
high dose acetylsalicylic acid is limited by the increased
risk of bleeding) [84]. Low dose acetylsalicylic acid (100
mg and 300 mg) had no effect on IL-6 or CRP levels in
patients with type 2 diabetes during 6 weeks [85]. Salsa-
late at a dose of 3 grams per day however does lower
fasting glucose levels and glucose levels after a oral glu-
cose tolerance test in patients with obesity, by increasing
insulin levels via an unknown mechanism [86]. In
patients with type 2 diabetes, salsalate in doses of 3 and
4,5 grams per day improved insulin resistance as mea-
sured during a hyperinsulinemic euglycemic clamp, fast-
ing and post challenge glucose levels, decreased free
fatty acid (FFA) levels and increased adiponectin levels
by 35-45% without an effect on bodyweight [87]. This
effect of salsalate on adipose tissue dysfunction may be
mediated by the before mentioned anti-inflammatory
effect or by the possible PPAR-g agonistic action of sali-
cylates, leading to a reduction in insulin resistance.
Beta-blockers
Although earlier reports have found a possible link
between the use of beta blockers and the development
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for their beneficial effects on adipose tissue dysfunction
[88,89]. The relation between beta-blockers and diabetes
can be explained by b2 receptor blockade, induced
reduction in thermogenesis and subsequent weight gain
[90-92]. A combined b1a n db2-adrenoceptor agonist is
capable of down regulating adiponectin and up regulat-
ing TNF-a mRNA in murine adipocytes [93].
Indeed, some of the newer beta blockers do have ben-
eficial effects on insulin resistance and adipokines with-
out changes in weight. For example nebivolol (5 mg
daily), which has b2 intrinsic sympaticomimetic action,
increases plasma adiponectin levels in overweight
patients with hypertension [94] Celiprolol (up to 400
mg daily), a combined b1 antagonist and b2 agonist
reduces plasma leptin levels without a change in body-
weight in patients with dyslipidemia [95].
Aldosterone antagonists
Inhibition of mineralcorticosteroid receptor activation by
use of aldosterone antagonists is used in the treatment of
heart failure and hypertension. Besides an effect on blood
pressure, spironolactone is capable of inhibiting TNF-a,
IL-6 and Interferon- g (IFN-g)p r o d u c t i o ni ni s o l a t e d
human mononuclear cells in vitro [96]. Far less is known
about the effect of aldosterone antagonists on adipose tis-
sue dysfunction. Adipose tissue is capable of producing an
unidentified mineralcorticoid releasing factor that may sti-
mulate aldosterone production [97]. The mineralcorticoid
receptor has an important role in adipocyte differentiation
as witnessed by diminished differentiation of 3T3-L1 adi-
pocytes in the presence of dexamethason and spironolac-
tone [98]. In obese diabetic mice, blocking the
mineralcorticoid receptor reduced the expression of proin-
flammatory cytokines in adipose tissue while it lead to an
increased expression of adiponectin in cardiac and adipose
tissue [99]. Further evidence for an important role for the
mineralcorticoid receptor in adipose tissue comes from a
study in obese mice where blocking the mineralcorticoid
receptor with eplererone ameliorated insulin resistance,
decreased the number of hypertrophic adipocytes and
infiltrating macrophages [100]. Furthermore, eplererone
was also capable of blunting aldosterone and H2O2
induced radical oxygen species and dysregulated expres-
sion of obesity related genes in 3T3-L1 adipocytes. This
data from in vitro and murine studies shows that aldoster-
one might play a relevant role in adipocyte biology.
Indeed, although not a strict adipokine, plasma PAI-1
levels were reduced by spironolactone in patients with
type 2 diabetes and diabetic nephropathy [101].
Angiotensin Converting Enzyme Inhibitors (ACE-i)
Angiotensin Converting Enzyme Inhibitors (ACE-i) are
widely used in the treatment of heart failure and
hypertension. In a large randomized trial, ramipril was
associated with a lower incidence of diabetes, compared
to placebo, in patients at high cardiovascular risk [102].
In patients with cardiovascular disease and impaired
fasting glucose, ramipril did not reduce the incidence of
diabetes mellitus but was associated with regression to
normoglycaemia [103].
Circulating levels of angiotensin II are associated with
changes in VAT in humans [104]. ACE-inhibitors may
affect insulin resistance by reducing plasma concentra-
tions of angiotensin II. Angiotensin II increases serine
phosphorylation of the insulin receptor, insulin receptor
substrate 1 and phophadidylinositol-3-kinase leading to
a state of insulin resistance [105]. Angiotensin II might
also influence insulin resistance via a direct pro-inflam-
matory effect on adipocytes and subsequent changes in
MCP-1, IL-6 and IL-8 production via the NF-Bp a t h -
way and increased production of leptin via an ERK1/2
dependent pathway in a murine model [106-108].
Finally, ACE-i decreases total body fat mass and plasma
leptin levels in a murine model [109].
Lisinopril binds to PPAR-g, although with a low bind-
ing affinity, suggesting a possible role for a PPAR-g ago-
nistic action for ACE-i [110]. ACE-i are less effective
than angiotensin II type 1 receptor blockers (ARB) in
raising plasma adiponectin levels [111-113], which is
likely a consequence of the different effects on PPAR-g.
Angiotensin II type 1 Receptor Blockers (ARB)
The ARB valsartan reduces the risk of developing type 2
diabetes mellitus in patients with hypertension [114]. In
clinical studies it is shown that insulin resistance is
indeed reduced by the use of ARBs [115,116]. Apart
from blockade of the angiotensin II type 1 receptor,
ARBs function as partial agonists of PPAR-g,e v e ni n
the absence of a functional AT-II receptor [117,118]. In
a murine model, plasma adiponectin levels were ele-
vated after treatment with irbesartan without a change
in adiponectin mRNA levels,s u g g e s t i n gap o s t - t r a n -
scriptional mechanism [119]. The effect on PPAR-g is
further shown by studies investigating the effect of
ARBs on adipose tissue distribution. Telmisartan
decreases VAT by 10%, as measured by CT, without
having an effect on subcutaneous fat area [120,121].
ARBs also have anti-inflammatory effects as seen by
lowering effect on plasma TNF-a and IL-6 levels in
patients with diabetes and hypertension [120,122] Tel-
misartan, but not valsartan, was shown to attenuate
TNF-a induced IL-6 production by vascular smooth
muscle cells in a PPAR-g dependent manner [123].
These PPAR-g agonistic effects of ARBs result in higher
plasma levels of adiponectin [120,121,124], although no
effect was observed on high-molecular weight adiponec-
tin levels [115,116].
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Statins might have a various direct effects on adipose
tissue function by inhibiting Toll-like receptor-4 (TLR4)
triggered expression of IFN-g in macrophages, which are
abundant in adipose tissue, and through increasing
PPAR- g expression [125,126]. Besides direct effects on
adipose tissue, statins are also capable of reducing
inflammation in general as measured by reduced plasma
CRP levels [127]. Incubation of murine 3T3-L1 adipo-
cytes with blood samples from patients treated with pra-
vastatin induced adiponectin production [128].
However, pravastatin, a hydrophilic statin [129], did not
alter insulin sensitivity, or leptin and adiponectin plasma
concentrations in healthy subjects [130]. Pravastatin
treatment however did elevate plasma adiponectin levels
more in patients with lower baseline levels compared to
patients with higher baseline adiponectin plasma con-
centrations [131,132].
Due to differences in lipophylicity, statins may have
different effects on adipose tissue function. Atorvastatin,
which is more lipophylic than pravastatin [129] increases
adiponectin levels in patients with coronary artery
disease (CAD) or at high risk for CAD while having
no effect on adiponectin in patients with diabetes
[133-136]. Simvastatin, the most lipophylic statin,
decreases adiponectin [137,138]. Rosuvastatin, a very
hydrophilic statin, was able to lower visfatin levels in
patients with increased risk for cardiovascular disease
while simvastatin had no effect [139,140]. This suggests
a beneficial effect of hydrophilic statins over lipophylic
statins on adipose tissue dysfunction. Initially statins
were thought to reduce the incidence of diabetes [141],
but two recent meta analyses of statin trials on the inci-
d e n c eo fd i a b e t e ss h o w e dt h a tt h e r ei sn oo re v e na
small increased risk of diabetes due to statin treatment
without clear heterogeneity between statins [142,143].
Fibrates
Fibrates decrease the incidence of type 2 diabetes melli-
tus [144], by a PPAR-a agonistic effect [145]. The
PPAR-a agonistic effects of fibrates also include an anti-
inflammatory regulatory action on macrophages by
interfering with the NF-B and AP-1 pathways [146].
Besides the PPAR-a agonistic effect, some fibrates like
bezafibrate, can be seen as pan-PPAR agonists and
therefore may have effects through PPAR-g and/or
PPAR-b/δ [147,148] As mentioned before, this could be
significant as especially PPAR-g is of major importance
for adipocyte differentiation and function. Fibrates inhi-
bit the expression of PAI-1 in human adipocytes and
preadipocytes, an effect which is blunted when cells are
co-incubated with a PPAR-a inhibitor [149]. In a mur-
ine model, fenofibrate increased adiponectin and visfatin
mRNA levels while decreasing the expression of TNF-a
in the VAT without an effect on serum TNF-a levels
[150]. Short-term treatment effects of fibrates on adi-
pose tissue function are seen by lower TNF-a,I L - 6 ,
PAI-1, MCP-1 and RBP-4 plasma levels during treat-
ment [151,152], and by an increase in high molecular
weight adiponectin levels by 12% in patients with hyper-
triglyceridemia [153].
Thiazolidinediones
Peroxisome Proliferator-Activated Receptors or PPARs
are ligand-activated transcription factors that belong to
the nuclear receptor superfamiliy. While the thiazolidi-
n e d i o n e( T Z D )r o s i g l i t a z o n ei sas e l e c t i v eP P A R - g ago-
nist, pioglitazone exerts PPAR-g and -a agonistic
activity which may account for the differential metabolic
effects of pioglitazone and rosiglitazone. Thiazolidine-
diones have been investigated as potential drugs in pre-
venting type 2 diabetes. Treatment with rosiglitazone
during 3 years lowered the incidence of diabetes melli-
tus type 2 (HR 0.38, 95% CI 0.33-0.44) [154].
Thiazolidinediones may directly increase insulin sensi-
tivity in the liver and adipose tissue where it is of critical
importance for adipocyte differentiation. Indeed, as a
consequence of PPAR-g agonism, thiazolidinediones
increase SAT-mass [155]. PPAR-g agonists are thought
to promote free fatty acid uptake and storage in adipo-
cytes and may therefore protect the liver and muscle
from excess levels of free fatty acids and their toxic
effects, resulting in insulin resistance. Also, PPAR-g ago-
nists may have indirect effects on insulin resistance by
altering adipocytokine production. Pioglitazone increases
high molecular weight adiponectin and decreases TNF-
a levels and RBP-4 levels in patients with type 2 dia-
betes [155-157].In addition, this effect of pioglitazone on
plasma levels of adiponectin is highly predictable on
baseline levels [158]. Rosiglitazone increases leptin levels
as would be expected due to the expansion of the SAT
compartment and has effects on adipocytokine produc-
tion as shown by lowering PAI-1 levels, which is partly
dependent on adiponectin, and increasing adiponectin
plasma levels [159-161]. Although PPAR-g agonists have
shown considerable beneficial effects on adipose tissue
function, concerns about cardiovascular safety remain.
Both thiazolidinediones are associated with a 3-4 kg
increase in bodyweight probably due to fluid retention
which leads to an increased risk for heart failure
[162,163] Rosiglitazone therapy is associated with an
increased risk for the occurrence of myocardial infarc-
tions which has lead to the withdrawal of this drug from
the market in 2010 [164]. As beneficial vascular effects
are seen with pioglitazone, current research is focussing
on other dual PPAR-a/g agonists to improve not only
glycemic control but also lipid levels and potentially
reducing vascular risk [165].
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Metformin reduces the incidence of type 2 diabetes in
patients with elevated fasting and post-load glucose con-
centrations indicating an effect of metformin in redu-
cing insulin resistance [166]. Apart from affecting
glucose uptake in the liver and in peripheral tissues,
metformin has anti-inflammatory properties by inhibit-
ing NF-B and blocking the PI3K-Akt pathway in
human vascular wall cells [167]. Recent evidence sug-
gests a possible role of metformin on AMP-activated
protein kinase dependent lipolysis in adipocytes which
may lead to lower plasma levels of fatty acids and there-
fore to improvement in adipose tissue function [168].
Production of PAI-1 by human subcutaneous adipose
tissue (SAT) is inhibited by metformin in vitro, showing
a potential direct effect of metformin on adipose tissue
function [169]. However in a study with lean and obese
patients with and without diabetes, metformin did not
result in a reduction of BMI, nor did it affect plasma
adiponectin levels after 4 months of treatment [170]
Other studies have shown that metformin decreases
plasma concentrations of MIF in obese patients and also
decreases vaspin while increasing omentin plasma
concentrations in overweight women with polycystic
ovary syndrome, without an effect on bodyweight
[171-173]. These results indicate a direct effect of met-
formin on adipose tissue in humans, beyond an effect
through weight reduction.A p a r tf r o mt h e s ed i r e c t
effects on adipose tissue function, metformin may also
work through effects on body composition. Metformin
does not affect the amount of VAT, but reduces SAT,
total body fat percentage, BMI and waist circumference
in obese children and adolescents [174]. It can be con-
cluded that metformin, which has an important place in
the treatment of type 2 diabetes, also has direct benefi-
cial effects on adipose tissue function.
Conclusion
O b e s i t yr e l a t e da d i p o s et i s s u ed y s f u n c t i o nm a yb ea n
important risk factor for the development of vascular dis-
eases and diabetes. Weight reduction and physical exer-
cise improve adipose tissue function, probably to a large
extent due to a reduction in fat mass. Various pharmaco-
logical agents commonly used in patients with vascular
diseases or diabetes mellitus also affect adipose tissue
function by various mechanisms (Table 1). Within classes
Table 1 Differential effects of currently available interventions in the treatment of adipose tissue dysfunction
Intervention Mechanism of action responsible for the effect on
cytokines and adipokines
Effect on cytokines and adipokines
Diet Weight loss Adiponectin↑, leptin↓, IL-6↓, sTNF-a receptor type 1↓
Orlistat Weight loss Adiponectin↑, resistin↓, leptin↓, IL-6↓, TNF-a↓
Sibutramine Weight loss Adiponectin↑, resistin↓, leptin↓, IL-10↑, TNF-a↓, IL-6↓
CB1-antagonists Weight loss Adiponectin↑, leptin↓
Effects through PPARg activation
Bariatric surgery Weight loss Adiponectin↑, HMW adiponectin↑, RBP-4↓, PAI-1↓,
MIF↓, MCP-1↓, IL-18↓
Effects on gut hormones
Exercise Weight loss Adiponectin↑, resistin↓, RBP-4↓, IL-6↓, IL-18↓
Salicylates Anti-inflammatory Adiponectin↑
COX-2 inhibition
b-blocker b2 adrenoreceptor activation Adiponectin ↑, leptin↓
Aldosteron antagonists Aldosteron antagonism PAI-1↓
Angiotensin Converting
Enzyme inhibitors
Inhibition of the renin-angiotensin system Adiponectin↑
Angiotensin II type 1 receptor
blockers
Inhibition of the renin-angiotensin system Adiponectin↑, TNF-a↓, IL-6↓
Effects through PPARg activation
(HMG-CoA) reductase
inhibitors
Anti-inflammatory Adiponectin↑↓, visfatin↓
Fibrates Effects through PPARa activation Adiponectin↑, RBP-4↓, PAI-1↓, MCP-1↓, TNF-a↓, IL-6↓
Effects through PPARg activation
Metformin Anti-inflammatory Vaspin↓, MIF↓
AMPK activation
Thiazolidinediones Effects through PPARg activation Adiponectin↑, HMW adiponectin↑, leptin↑, RBP-4↓,
PAI-1↓
AMPK: AMP activated protein kinase, CB-1 antagonists: Cannabinoid-1 antagonist, IL: Interleukin, MCP-1: Monocyte chemoattractant protein-1, MIF: Macrophage
Inhibitory Factor, PAI-1: Plasminogen activator inhibitor-1, PPAR: Peroxisome Proliferator Activated Receptors, RBP-4: Retinol Binding Protein4 ,T N F - a: Tumor
Necrosis Factor-a.
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Page 7 of 12of drugs there are differential effects of individual phar-
macological agents. Although the effects of these drugs
on adipose tissue function are unintended, improving adi-
pose tissue function may contribute to reducing the risk
of vascular diseases and the development of type 2 dia-
betes. However, the clinical relevance of influencing adi-
pose tissue function remains to be determined.
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